The use of diazoxide in the management of spontaneous hypoglycemia in patients with ESRD

Abstract Although diabetes remains the number one cause of renal failure nationwide, spontaneous hypoglycemia in patients with CKD has also been described in the absence of exogenous insulin or any other diabetes treatment. Decreased renal gluconeogenesis and impaired renal insulin clearance are underlying mechanisms of hypoglycemia in individuals with ESRD. Diazoxide was originally approved as an anti-hypertensive medication, but also is known to bind ATP-sensitive K channels in the beta cells of the pancreas, ultimately leading to inhibition of insulin release. We detail six cases of ESRD-associated hypoglycemia which responded to treatment with diazoxide therapy..

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:9

Enthalten in:

CEN Case Reports - 9(2020), 3 vom: 09. Apr., Seite 271-277

Sprache:

Englisch

Beteiligte Personen:

Mesmar, Bayan [VerfasserIn]
Kristan, Megan [VerfasserIn]
Satyarengga, Medha [VerfasserIn]
Lamos, Elizabeth M. [VerfasserIn]
Malek, Rana [VerfasserIn]
Munir, Kashif M. [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

Themen:

Diazoxide
ESRD
Hypoglycaemia

Anmerkungen:

© Japanese Society of Nephrology 2020

doi:

10.1007/s13730-020-00471-z

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2118137915